No Picture
News

Ebola trial stopped early as Regeneron, Ridgeback therapies cut death risk; Merck inks deal to test Keytruda with Oncologie’s antibody

? As armed rebels conflict with containment efforts to thwart the deadly Ebola virus in the Congo, a trial testing the viability of four experimental therapies (from MappBio/ZMapp, Gilead $GILD/remdesivir, Regeneron $REGB/REGN-EB3, and Ridgeback Biothe… […]